Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis

Conclusions
Older age is associated with a lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS. Our findings inform the design of RCTs, and suggest that patient age should be taken into consideration when deciding on immunomodulatory treatment in RRMS.

Source: Journal of Neurology, Neurosurgery and Psychiatry - September 14, 2023 Category: Neurosurgery Authors: Strijbis, E. M., Coerver, E., Mostert, J., van Kempen, Z. L. E., Killestein, J., Comtois, J., Repovic, P., Bowen, J. D., Cutter, G., Koch, M. Tags: Multiple sclerosis Source Type: research